GeoVax to Raise Approximately $3.2 Million of Gross Proceeds in Public OfferingSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax to Raise Approximately $3.2 Million of Gross Proceeds in Public OfferingATLANTA, GA - December 19, 2025 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into definitive securities purchase agreements with several institutional and individual investors for the purchase and sale of approximately 13.2 million units, each comprised of one share of the Company's common stock and warrants, as described below, to purchase shares of the Company’s common stock, at a price of $0.245 per unit in a public offering. The Company will issue warrants to purchase up to approximately 26.5 million shares of common stock. The warrants will have an exercise price of $0.245 per share, will be exercisable immediately following the date of issuance and will have a term of five years following the date of issuance.
GeoVax Announces Publication of Study Demonstrating Cross-Variant Protection Using the Multi-Antigen GEO-CM04S1 VaccineSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Announces Publication of Study Demonstrating Cross-Variant Protection Using the Multi-Antigen GEO-CM04S1 VaccineAnimal Models Show Full Protection Against Omicron Variant Despite Absence of Neutralizing Antibodies, Highlighting Critical Importance of T-cell Immunity for Next-generation COVID-19 Vaccines
GeoVax Receives Formal EMA Scientific Advice Supporting Pivotal Phase 3 Immunobridging Trial for GEO-MVAEMA Concurrence Enables Acceleration Toward Phase 3 Initiation and Represents a Major Milestone on GeoVax’s Path to Commercialization
GeoVax Addresses Identification of New Mpox VariantContinued Mpox Evolution Underscores Dependence on a Single Global Supplier, Reinforcing the Critical Importance of GeoVax’s Accelerated GEO-MVA Program
GeoVax Receives Formal EMA Scientific Advice Supporting Pivotal Phase 3 Immunobridging Trial for GEO-MVASearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Announces Completion of GEO-MVA Fill-Finish, Supporting Phase 3 Immunobridging Clinical Trial Start-Up in Early 2026Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Receives U.S. Patent Office Notice of Allowance for Broad-Spectrum COVID-19 Vaccine DesignSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Receives U.S. Patent Office Notice of Allowance for Broad-Spectrum COVID-19 Vaccine DesignPatent Strengthens GeoVax’s Multi-Antigen Vaccine Platform Designed to Deliver Broader, Longer-Lasting Protection and Support Future Pandemic Preparedness
GeoVax Announces Addition of Renowned Global Experts to Its Scientific Advisory BoardNewly Appointed Members Include Leaders in Vaccine Immunology, T-Cell Science, and Clinical Research
GeoVax Announces British Journal of Haematology Publication Highlighting Superior T-Cell Responses of GEO-CM04S1 in CLL PatientsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Addresses Identification of New Mpox VariantSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Announces Addition of Renowned Global Experts to Its Scientific Advisory BoardSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Announces Issuance of U.S. Patent Covering Enhanced Therapeutic Use of Gedeptin(R) Gene TherapySearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Announces Issuance of U.S. Patent Covering Enhanced Therapeutic Use of Gedeptin(R) Gene TherapyPatent Protects Novel Application of Gedeptin Therapy Across Multiple Solid Tumor Types; Supports Expansion of Gedeptin Product Platform
GeoVax to Present at the Noble Capital Markets Twenty-First Annual Emerging Growth Equity ConferenceATLANTA, GA - November 24, 2025 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman & CEO, David Dodd, will present at NobleCon21 - the Noble Capital Markets Twenty-First Annual Emerging Growth Equity Conference taking place December 2-3, 2025 in Boca Raton, FL.
GeoVax to Present at the Noble Capital Markets Twenty-First Annual Emerging Growth Equity ConferenceSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Reports Third Quarter 2025 Financial Results and Provides Business UpdateSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Reports Third Quarter 2025 Financial Results and Provides Business UpdateQuarter Highlighted by GEO-MVA Acceleration Amid Global Mpox Emergency, Gedeptin® Expansion Into New Solid Tumor Programs, and Strong GEO-CM04S1 Clinical Data in Immunocompromised Patients
GeoVax Recognizes World Immunization Day: Advancing Innovation and Trust in VaccinationSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
